Neurocrine Biosciences Inc. filings document the regulatory record of a commercial biopharmaceutical company developing and selling treatments for neurological, psychiatric, endocrine and immunological disorders. Its 8-K reports cover operating and financial results, product-sales disclosures, clinical or regulatory updates, material agreements, capital-structure matters and executive or employment-related governance events.
Proxy filings describe board matters, shareholder voting items, executive compensation, equity awards and pay-versus-performance disclosures. The filing record also includes formal disclosures related to INGREZZA, CRENESSITY and the company's pipeline, as well as risk, governance and transaction-related disclosure categories relevant to its public-company status.
Neurocrine Biosciences’ Chief Human Resources Officer Julie Cooke reported RSU vesting and tax withholding transactions. On January 31, 2026, 1,741 restricted stock units converted into the same number of common shares at $0 exercise price. To cover taxes, 997 shares of common stock were withheld at $136.06 per share, and no shares were sold on the market.
After these transactions, Cooke beneficially owned 27,602 shares of Neurocrine common stock, including 25,738 shares held by the Cooke Family Trust of 2004, over which she has voting and investment power. Each RSU represents the right to receive one share of common stock.
Neurocrine Biosciences’ Chief Regulatory Officer, Ingrid Delaet, reported routine equity compensation activity. On January 31, 2026, 801 restricted stock units vested and were converted into 801 shares of common stock at an exercise price of $0.
To cover tax withholding on this vesting, 475 shares were withheld by the company at $136.06 per share, as noted in the footnotes, and no shares were sold on the market. After these transactions, Delaet directly owned 5,056 shares of Neurocrine Biosciences common stock.
Neurocrine Biosciences Chief Executive Officer Kyle Gano reported routine equity compensation activity. On January 31, 2026, 2,927 restricted stock units vested and were converted into an equal number of common shares at an exercise price of $0, reflecting previously granted stock awards.
On the same date, 1,580 common shares were withheld by Neurocrine Biosciences at a price of $136.06 per share to cover tax withholding obligations related to this vesting, and the filing states that no shares were sold. Following these transactions, Gano directly owned 141,754 shares of Neurocrine Biosciences common stock.
Neurocrine Biosciences director Kevin Charles Gorman reported routine equity compensation activity. On January 31, 2026, 5,142 restricted stock units converted into the same number of Neurocrine common shares at $0 exercise price. To cover taxes on this vesting, 2,845 shares were withheld by the company at $136.06 per share, and no shares were sold on the market.
After these transactions, Gorman beneficially owned 516,893 common shares, held by the Gorman and Blais Family Trust, over which he has voting and investment power. The vesting completed an RSU grant originally awarded on January 31, 2022.
On January 31, 2026, Neurocrine Biosciences Chief Legal Officer Darin Lippoldt had 2,373 restricted stock units (RSUs) convert into common stock at an exercise price of $0. Each RSU represents the right to receive one share of common stock.
To satisfy tax withholding on this RSU vesting, the company withheld 1,335 shares of common stock at a price of $136.06 per share. The company states that no shares were sold in the market. Following these transactions, Lippoldt directly owned 47,792 shares of Neurocrine Biosciences common stock.
Neurocrine Biosciences Chief Scientific Officer Jude Onyia reported routine equity compensation activity. On January 31, 2026, 238 restricted stock units converted into 238 shares of common stock at an exercise price of $0, increasing Onyia’s direct holdings to 16,119 shares.
On the same date, 142 of those shares were withheld by Neurocrine Biosciences at $136.06 per share to cover tax obligations tied to the RSU vesting, as disclosed in the footnotes. No shares were sold in the open market, and Onyia’s direct ownership after withholding was 15,977 common shares.
JPMorgan Chase & Co. has filed a Schedule 13G reporting a passive ownership stake in Neurocrine Biosciences, Inc. common stock. As of 12/31/2025, JPMorgan reports beneficial ownership of 5,198,084 shares, representing 5.2% of Neurocrine’s common stock.
The filing shows JPMorgan has sole voting power over 4,705,046 shares and shared voting power over 21,535 shares. It has sole dispositive power over 5,196,778 shares and shared dispositive power over 1,221 shares. JPMorgan is identified as a Delaware holding company with several subsidiaries, including J.P. Morgan Securities LLC and JPMorgan Chase Bank, National Association.
JPMorgan certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Neurocrine Biosciences.
Neurocrine Biosciences' Chief Executive Officer Kyle Gano reported option exercises and related stock sales. On January 16, 2026, he exercised non-qualified stock options and incentive stock options to acquire 34,588 and 1,812 shares of common stock, respectively, at an exercise price of $35.99 per share. On the same date, he sold 34,588 shares at a weighted average price of $132.7044 per share and 1,812 shares at a weighted average price of $132.7143 per share under a pre-established Rule 10b5-1 trading plan adopted on May 20, 2025. After these transactions, he directly owned 140,407 shares of Neurocrine Biosciences common stock. The exercised options were granted on February 5, 2016 and were scheduled to expire on February 5, 2026.
Neurocrine Biosciences Chief Commercial Officer filed an amended Form 4 to correct a previously misreported stock option exercise. On November 28, 2025, the insider exercised 12,830 incentive stock options, rather than the 5,970 options originally reported. The options had an exercise price of $35.99 per share and converted into an equal number of common shares. The filing also updates the insider’s reported beneficial ownership of Neurocrine Biosciences common stock and notes that this total includes 204 shares acquired through the company’s 2018 Employee Stock Purchase Plan. The incentive stock option was granted on February 5, 2016, vested in 48 equal monthly installments beginning March 5, 2016, and was scheduled to expire on February 5, 2026.
A holder of NBIX common stock has filed a notice of proposed sale under Rule 144, covering 36,400 common shares with an aggregate market value of $4,853,940. The shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an approximate sale date of 01/16/2026. Common shares outstanding were 99,705,698 as of this notice.
The 36,400 shares were acquired on 01/16/2026 by exercising stock options granted by the issuer and paid for in cash. In the past three months, the seller listed as Kyle Gano previously sold 300 common shares on 11/04/2025 for gross proceeds of $42,591. By signing the notice, the seller represents that they do not know of any undisclosed material adverse information about the issuer’s operations.